FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3010976886> ?p ?o ?g. }

• W3010976886 endingPage "69" @default.
• W3010976886 startingPage "61" @default.
• W3010976886 abstract "PURPOSE: The assessment of possibility to add a new indication for the registered pharmaceutical. Evaluation of safety and efficacy of Visomitin® compared to placebo in patients with age-related cataracts. METHODS: A randomized, double-blind, placebo-controlled clinical study of Visomitin® eye drops in patients with age-related cataracts was conducted in accordance with Good Clinical Practice guidance, the Declaration of Helsinki and the Russian regulatory requirements. The study included 80 patients (23 men and 57 women) aged 45 to 75 years with diagnosed age-related cataract. All subjects were randomized into two groups of 40 patients each. In the treatment group patients received Visomitin® eye drops and in the control group, patients were given placebo (vehicle, i.e. eye drops with the same composition as Visomitin® except for the active substance SkQ1) in the form of instillations of one drop per each eye three times daily for six months. The study comprised 7 monthly visits. The following standard ophthalmological examinations were used to evaluate the effectiveness of the therapy: visual acuity measurement, refractometry, biomicroscopy of the eye, ophthalmoscopy, tonometry, computer perimetry, densitometry. At certain visits lacrimal fluid was taken for evaluation of its antioxidant activity. Blood pressure and heart rate were measured as a part of safety evaluation which also included documentation of complaints and adverse events. Concomitant therapies were also documented. RESULTS: Analysis of safety parameters showed Visomitin® to be safe and well tolerated for patients with age-related cataract. Practically no adverse effects were documented during the study. In both groups a decrease of the number of patients with subjective complaints was observed. These complaints included: visual deterioration, dryness, grittiness, burning eyes, eye fatigue. The decrease of the number of complaints in the Visomitin® group was more pronounced than in the placebo group. During the first months of treatment an improvement of visual acuity was observed in both groups. This result can be explained by a protective effect of hypromellose contained in both Visomitin® and placebo. However, between the 4th and the 6th months, the improvement in visual acuity significantly slowed down in the placebo group, while positive dynamics remained the same in the Visomitin® group. At the end of the treatment visual acuity increased by more than 50% in Visomitin® group and remained at the level of 10-15% in the placebo group (statistically significant difference between placebo and Visomitin® groups, p<0.05). Even more pronounced difference was detected for older patients, where placebo did not cause any increase in visual acuity (p<0.001 at the end of the treatment). A tendency for decrease of the mean and maximum density of the lens was found in the group of patients treated with Visomitin®. On the contrary in the placebo group both mean and maximum density of the lens tended to increase. It is reasonable to suggest that these effects of Visomitin® resulted from an increase of antioxidant protection of eye that was verified by the measurement of the antioxidant activity of lacrimal fluid in the study. After 6 months of treatment antioxidant activity of lacrimal fluid significantly increased in the group of patients treated with Visomitin® compared to that in the placebo group. CONCLUSION: Study results support the use of Visomitin® as effective and safe treatment of age-related cataract. Such treatment can be aimed at deceleration of the disease progression in order to delay surgery. The study results allowed adding a new indication for the use of Visomitin® eye drops." @default.
• W3010976886 created "2020-03-23" @default.
• W3010976886 creator A5022594605 @default.
• W3010976886 creator A5031565417 @default.
• W3010976886 creator A5032388937 @default.
• W3010976886 creator A5034249553 @default.
• W3010976886 creator A5038219811 @default.
• W3010976886 creator A5049151575 @default.
• W3010976886 creator A5050046672 @default.
• W3010976886 creator A5055381157 @default.
• W3010976886 creator A5056961645 @default.
• W3010976886 creator A5060258873 @default.
• W3010976886 creator A5061844898 @default.
• W3010976886 creator A5067342238 @default.
• W3010976886 creator A5074895787 @default.
• W3010976886 creator A5080615918 @default.
• W3010976886 creator A5081416317 @default.
• W3010976886 creator A5082130547 @default.
• W3010976886 date "2016-01-01" @default.
• W3010976886 modified "2023-10-01" @default.
• W3010976886 title "Efficacy and safety of Visomitin® eye drops, in patients with age-related cataract: a randomized, double-blind, placebo-controlled clinical study" @default.
• W3010976886 hasPublicationYear "2016" @default.
• W3010976886 type Work @default.
• W3010976886 sameAs 3010976886 @default.
• W3010976886 citedByCount "0" @default.
• W3010976886 crossrefType "journal-article" @default.
• W3010976886 hasAuthorship W3010976886A5022594605 @default.
• W3010976886 hasAuthorship W3010976886A5031565417 @default.
• W3010976886 hasAuthorship W3010976886A5032388937 @default.
• W3010976886 hasAuthorship W3010976886A5034249553 @default.
• W3010976886 hasAuthorship W3010976886A5038219811 @default.
• W3010976886 hasAuthorship W3010976886A5049151575 @default.
• W3010976886 hasAuthorship W3010976886A5050046672 @default.
• W3010976886 hasAuthorship W3010976886A5055381157 @default.
• W3010976886 hasAuthorship W3010976886A5056961645 @default.
• W3010976886 hasAuthorship W3010976886A5060258873 @default.
• W3010976886 hasAuthorship W3010976886A5061844898 @default.
• W3010976886 hasAuthorship W3010976886A5067342238 @default.
• W3010976886 hasAuthorship W3010976886A5074895787 @default.
• W3010976886 hasAuthorship W3010976886A5080615918 @default.
• W3010976886 hasAuthorship W3010976886A5081416317 @default.
• W3010976886 hasAuthorship W3010976886A5082130547 @default.
• W3010976886 hasConcept C118487528 @default.
• W3010976886 hasConcept C126322002 @default.
• W3010976886 hasConcept C141071460 @default.
• W3010976886 hasConcept C142724271 @default.
• W3010976886 hasConcept C168563851 @default.
• W3010976886 hasConcept C197934379 @default.
• W3010976886 hasConcept C204787440 @default.
• W3010976886 hasConcept C27081682 @default.
• W3010976886 hasConcept C2777155141 @default.
• W3010976886 hasConcept C2777625524 @default.
• W3010976886 hasConcept C2778257484 @default.
• W3010976886 hasConcept C2780225610 @default.
• W3010976886 hasConcept C535046627 @default.
• W3010976886 hasConcept C71924100 @default.
• W3010976886 hasConceptScore W3010976886C118487528 @default.
• W3010976886 hasConceptScore W3010976886C126322002 @default.
• W3010976886 hasConceptScore W3010976886C141071460 @default.
• W3010976886 hasConceptScore W3010976886C142724271 @default.
• W3010976886 hasConceptScore W3010976886C168563851 @default.
• W3010976886 hasConceptScore W3010976886C197934379 @default.
• W3010976886 hasConceptScore W3010976886C204787440 @default.
• W3010976886 hasConceptScore W3010976886C27081682 @default.
• W3010976886 hasConceptScore W3010976886C2777155141 @default.
• W3010976886 hasConceptScore W3010976886C2777625524 @default.
• W3010976886 hasConceptScore W3010976886C2778257484 @default.
• W3010976886 hasConceptScore W3010976886C2780225610 @default.
• W3010976886 hasConceptScore W3010976886C535046627 @default.
• W3010976886 hasConceptScore W3010976886C71924100 @default.
• W3010976886 hasIssue "1" @default.
• W3010976886 hasOpenAccess W3010976886 @default.
• W3010976886 hasRelatedWork W126868392 @default.
• W3010976886 hasRelatedWork W146570412 @default.
• W3010976886 hasRelatedWork W1489704469 @default.
• W3010976886 hasRelatedWork W1492606441 @default.
• W3010976886 hasRelatedWork W1979402451 @default.
• W3010976886 hasRelatedWork W1982450750 @default.
• W3010976886 hasRelatedWork W2008448108 @default.
• W3010976886 hasRelatedWork W2040842994 @default.
• W3010976886 hasRelatedWork W2053064928 @default.
• W3010976886 hasRelatedWork W2074980857 @default.
• W3010976886 hasRelatedWork W2402526976 @default.
• W3010976886 hasRelatedWork W2463875838 @default.
• W3010976886 hasRelatedWork W3002923181 @default.
• W3010976886 hasRelatedWork W3090854 @default.
• W3010976886 hasRelatedWork W3112250676 @default.
• W3010976886 hasRelatedWork W3131578737 @default.
• W3010976886 hasRelatedWork W70177976 @default.
• W3010976886 hasRelatedWork W181243166 @default.
• W3010976886 hasRelatedWork W2182262220 @default.
• W3010976886 hasRelatedWork W2341348551 @default.
• W3010976886 hasVolume "15" @default.
• W3010976886 isParatext "false" @default.
• W3010976886 isRetracted "false" @default.
• W3010976886 magId "3010976886" @default.
• W3010976886 workType "article" @default.